ANS03 for solid tumors with ROS1 or NTRK changes
Part of Cancer clinical trials.
This trial tests a new drug called ANS03 for people with certain genetic changes (ROS1 or NTRK) in their solid tumors. The goal is to see if ANS03 can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your cancer is locally advanced (has spread nearby) or has spread to other parts of the body (metastatic)
- You have a specific genetic change in your tumor called ROS1 or NTRK
- You are generally able to take care of yourself (ECOG performance status 0-2)
- Your cancer can be measured on scans (like CT or MRI)
- Your organs and bone marrow are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Hear when a new Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.